Skip to Content
Merck
All Photos(1)

Documents

PZ0295

Sigma-Aldrich

Tiplaxtinin

≥98% (HPLC)

Synonym(s):

(1-Benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)oxoacetic acid; a-Oxo-1-(phenylmethyl)-5-[4-(trifluoromethoxy)phenyl]-1H-indole-3-acetic acid, PAI 039, PAI-039, Tiplasinin, WAY-168039

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H16F3NO4
CAS Number:
393105-53-8
Molecular Weight:
439.38
MDL number:
MFCD09475615
UNSPSC Code:
41106609
PubChem Substance ID:
329823818
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

SMILES string

O=C(C(O)=O)C1=CN(CC2=CC=CC=C2)C3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=C31

InChI

1S/C24H16F3NO4/c25-24(26,27)32-18-9-6-16(7-10-18)17-8-11-21-19(12-17)20(22(29)23(30)31)14-28(21)13-15-4-2-1-3-5-15/h1-12,14H,13H2,(H,30,31)

InChI key

ODXQFEWQSHNQNI-UHFFFAOYSA-N

Biochem/physiol Actions

Tiplaxtinin has high oral bioavailability. It is metabolically stable and shows large safety multiples in animal toxicology studies. Tiplaxtinin can be easily synthesized in bulk quantities. This drug also reduces diet-induced obesity in mice.
Tiplaxtinin is a potent and selective PAI-1 inhibitor. Tiplaxtinin demonstrated efficacy in vivo in multiple models of acute arterial thrombosis and has been shown to reduce physiologic PAI-1 activity.

Hazard Statements

H413

Precautionary Statements

P273 - P501

Hazard Classifications

Aquatic Chronic 4

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.
Elokdah H, et al.
Journal of Medicinal Chemistry, 47(14), 3491-3494 (2004)
Tiplaxtinin impairs nutritionally induced obesity in mice.
Lijnen H R, et al.
Thrombosis and Haemostasis, 95(06), 731-737 (2006)
Camille Cohen et al.
EMBO molecular medicine, 13(11), e14146-e14146 (2021-11-03)
The mechanisms underlying the development of glomerular lesions during aging are largely unknown. It has been suggested that senescence might play a role, but the pathophysiological link between senescence and lesion development remains unexplained. Here, we uncovered an unexpected role

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service